Natural History, Trial Readiness and Gene Discovery: Advances in Patient Registries for Neuromuscular Disease

  • Rachel Thompson
  • Agata Robertson
  • Hanns Lochmüller
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1031)

Abstract

Inherited neuromuscular diseases (NMDs) are genetic disorders that affect the skeletal muscles or the nerves controlling muscle function. With a new generation of diagnostic options and recent advances in translational research improving the opportunities for therapy development for these rare conditions, capturing patient information in databases collecting a range of clinical and genetic data together with contact details has assumed an increasingly important role in trial planning and recruitment as well as natural history data collection. Here we provide an overview of a decade of patient registration activities in the NMD field, with a particular focus on patient registries set up with trial readiness in mind. A summary is provided of databases collecting precise genetic information focused on confirming the causative mutation and their evolution into registries that combine genetic data with additional clinical information useful for trial feasibility and recruitment. Use of these systems for a range of purposes beyond trial recruitment, including natural history assessment, care standards monitoring, genotype-phenotype correlation and disease burden evaluation is also described within the context of research networks (TREAT-NMD) and European Reference Networks (ERN-EURO-NMD). New initiatives including registries using controlled vocabularies for computational accessibility that focus on phenotypic data capture for gene discovery are analysed, and examples of the lessons learned at every stage are provided in order to allow new patient registration initiatives to benefit from the extensive experience gained.

Keywords

Neuromuscular disease NMD Trial readiness Trial recruitment Natural history Data sharing Interoperability Phenotype ontologies Next-generation sequencing Genetic databases Patient registries 

Notes

Acknowledgments

This work was funded by the UK Medical Research Council (MRC) Centre for Neuromuscular Diseases (reference G1002274, grant ID 98482) and by MRC grant number G0900872. HL receives funding from the European Commission through the projects NeurOmics (Grant No. 305121) and RD-Connect (Grant No. 305444). AR receives funding from SMA Support UK and the LGMD2I Research Fund. RT is funded by the European Commission through RD-Connect (No. 305444). The authors wish to acknowledge Rebecca Leary, Anne Oyewole, Oksana Pogoryelova and Elizabeth Wood for insight and information on individual registry initiatives related to TREAT-NMD, as well as the members of the TREAT-NMD executive committee and global database oversight committee (TGDOC).

References

  1. 1.
    Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation) (Text with EEA relevance), (2016)Google Scholar
  2. 2.
    Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ et al (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30(3):293–299CrossRefPubMedGoogle Scholar
  3. 3.
    Beroud C, Collod-Beroud G, Boileau C, Soussi T, Junien C (2000) UMD (Universal mutation database): a generic software to build and analyze locus-specific databases. Hum Mutat 15(1):86–94CrossRefPubMedGoogle Scholar
  4. 4.
    Bladen CL, Rafferty K, Straub V, Monges S, Moresco A, Dawkins H et al (2013) The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. Hum Mutat 34(11):1449–1457CrossRefPubMedGoogle Scholar
  5. 5.
    Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K et al (2015) The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum Mutat 36(4):395–402CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bladen CL, Thompson R, Jackson JM, Garland C, Wegel C, Ambrosini A et al (2014) Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. J Neurol 261(1):152–163CrossRefPubMedGoogle Scholar
  7. 7.
    Brabec P, Vondracek P, Klimes D, Baumeister S, Lochmuller H, Pavlik T et al (2009) Characterization of the DMD/BMD patient population in Czech Republic and Slovakia using an innovative registry approach. Neuromuscul Disord 19(4):250–254CrossRefPubMedGoogle Scholar
  8. 8.
    Bushby K, Connor E (2011) Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig 1(9):1217–1235CrossRefGoogle Scholar
  9. 9.
    Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9(1):77–93CrossRefPubMedGoogle Scholar
  10. 10.
    Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9(2):177–189CrossRefPubMedGoogle Scholar
  11. 11.
    Bushby K, Lynn S, Straub V (2009) Collaborating to bring new therapies to the patient--the TREAT-NMD model. Acta Myol 28(1):12–15PubMedPubMedCentralGoogle Scholar
  12. 12.
    Coorevits P, Sundgren M, Klein GO, Bahr A, Claerhout B, Daniel C et al (2013) Electronic health records: new opportunities for clinical research. J Intern Med 274(6):547–560CrossRefPubMedGoogle Scholar
  13. 13.
    DeMuro C, Clark M, Doward L, Evans E, Mordin M, Gnanasakthy A (2013) Assessment of PRO label claims granted by the FDA as compared to the EMA (2006–2010). Value in Health, J Int Soc Pharmacoecon Outcomes Res 16(8):1150–1155CrossRefGoogle Scholar
  14. 14.
    Dogan C, Puymirat J, Bassez G (2015) DM-SCOPE, an intermediary appraisal report and benefits of databases in neuromuscular disorders. Med Sci, M/S. 31 Spec No 3:18–9Google Scholar
  15. 15.
    Dutch Techcentre for Life Sciences. The Personal Health Train initiative. http://www.dtls.nl/fair-data/personal-health-train/. Accessed 1 July 2016
  16. 16.
    Eagle M, Bourke J, Bullock R, Gibson M, Mehta J, Giddings D et al (2007) Managing Duchenne muscular dystrophy--the additive effect of spinal surgery and home nocturnal ventilation in improving survival. Neuromuscul Disord 17(6):470–475CrossRefPubMedGoogle Scholar
  17. 17.
    European Union Committee of Experts on Rare Diseases. EUCERD Recommendations on Quality Criteria for Centres of Expertise for Rare Diseases in Member States. http://www.EUCERD.eu/upload/file/EUCERDRecommendationCE.pdf. 2011 Accessed 1 July 2016
  18. 18.
    European Union Committee of Experts on Rare Diseases. EUCERD Core Recommendations on Rare Disease Patient Registration and Data Collection. http://www.eucerd.eu/wp-content/uploads/2013/06/EUCERD_Recommendations_RDRegistryDataCollection_adopted.pdf. 2013 Accessed 1 July 2016
  19. 19.
    Evangelista T, Hedley V, Atalaia A, Johnson M, Lynn S, Le Cam Y et al (2016) The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks. Orphanet J Rare Dis 11:17CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Evangelista T, Wood L, Fernandez-Torron R, Williams M, Smith D, Lunt P et al (2016) Design, set-up and utility of the UK facioscapulohumeral muscular dystrophy patient registry. J Neurol 263(7):1401–1408CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Fokkema IF, Taschner PE, Schaafsma GC, Celli J, Laros JF, den Dunnen JTLOVD (2011) v.2.0: the next generation in gene variant databases. Hum Mutat 32(5):557–563CrossRefPubMedGoogle Scholar
  22. 22.
    Gainotti S, Turner C, Woods S, Kole A, McCormack P, Lochmuller H et al (2016) Improving the informed consent process in international collaborative rare disease research: effective consent for effective research. Eur J Hum Genet 24(9):1248–1254CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    GNEM-DMP consortium The GNE myopathy disease monitoring program (GNEM-DMP). www.gnem-dmp.com/. Accessed 1 July 2016
  24. 24.
    Gonzalez M, Falk MJ, Gai X, Postrel R, Schule R, Zuchner S (2015 Oct) Innovative genomic collaboration using the GENESIS (GEM.app) platform. Hum Mutat 36(10):950–956CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Hall A, Sireau N (eds) (2016) The patient group handbook: a practical guide for research and drug development. Create Space Independent Publishing Platform, North CharlestonGoogle Scholar
  26. 26.
    Hansson MG, van Ommen GJ, Chadwick R, Dillner J (2013) Patients would benefit from simplified ethical review and consent procedure. Lancet Oncol 14(6):451–453CrossRefPubMedGoogle Scholar
  27. 27.
    Heslop E, Csimma C, Straub V, McCall J, Nagaraju K, Wagner KR et al (2015) The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development. Orphanet J Rare Dis 10(1):49CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Kaplan J-C, Hamroun D (2015) The 2016 version of the gene table of monogenic neuromuscular disorders (nuclear genome). Neuromuscul Disord 25(12):991–1020CrossRefPubMedGoogle Scholar
  29. 29.
    Kirschner J, Schessl J, Schara U, Reitter B, Stettner GM, Hobbiebrunken E et al (2010) Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial. Lancet Neurol 9(11):1053–1059CrossRefPubMedGoogle Scholar
  30. 30.
    Köhler S, Vasilevsky NA, Engelstad M, Foster E, McMurry J, Aymé S et al (2017) The Human Phenotype Ontology in 2017. Nucleic Acids Res 4;45(D1):D865–D876Google Scholar
  31. 31.
    Korngut L, Campbell C, Johnston M, Benstead T, Genge A, Mackenzie A et al (2013) The CNDR: collaborating to translate new therapies for Canadians. Can J Neurol Sci 40(5):698–704Google Scholar
  32. 32.
    Landfeldt E, Alfredsson L, Straub V, Lochmuller H, Bushby K, Lindgren P (2017) Economic evaluation in Duchenne muscular dystrophy: model frameworks for cost-effectiveness analysis. Pharmacoeconomics 35(2):249–258Google Scholar
  33. 33.
    Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V et al (2014) The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology 83(6):529–536CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V et al (2015) Compliance to care guidelines for Duchenne muscular dystrophy. J Neuromuscul Dis 2(1):63–72PubMedPubMedCentralGoogle Scholar
  35. 35.
    Lochmuller H, Le Cam Y, Jonker AH, Lau LP, Baynam G, Kaufmann P et al (2017) ‘IRDiRC Recognized Resources’: a new mechanism to support scientists to conduct efficient, high-quality research for rare diseases. Eur J Hum Genet 25(2):162–165Google Scholar
  36. 36.
    Mascalzoni D, Dove ES, Rubinstein Y, Dawkins HJS, Kole A, McCormack P et al (2014) International Charter of principles for sharing bio-specimens and data. Eur J Hum Genet 23(6):721–728CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    McCormack P, Kole A, Gainotti S, Mascalzoni D, Molster C, Lochmuller H et al (2016) ‘You should at least ask’. The expectations, hopes and fears of rare disease patients on large-scale data and biomaterial sharing for genomics research. Eur J Hum Genet 24(10):1403–1408CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    McCormack P, Woods S, Aartsma-Rus A, Hagger L, Herczegfalvi A, Heslop E, et al (2013) Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: “translating” the translational. PLoS Curr 10(5)Google Scholar
  39. 39.
    Mercuri E, Mayhew A, Muntoni F, Messina S, Straub V, Van Ommen GJ et al (2008) Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12th--13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June--1st July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France. Neuromuscul Disord 18(11):894–903CrossRefPubMedGoogle Scholar
  40. 40.
    Mora M, Angelini C, Bignami F, Bodin A-M, Crimi M, Di Donato J-H, et al (2015) The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking for rare diseases. Eur J Hum Genet 23(9):1116–1123Google Scholar
  41. 41.
    NeurOmics Project Consortium. NeurOmics website. http://rd-neuromics.eu/. Accessed 1 July 2016
  42. 42.
    Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V (2009) Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 132(Pt 11):3175–3186CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Philippakis AA, Azzariti DR, Beltran S, Brookes AJ, Brownstein CA, Brudno M et al (2015) The Matchmaker Exchange: a platform for rare disease gene discovery. Hum Mutat 36(10):915–921CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Rahbek J, Werge B, Madsen A, Marquardt J, Steffensen BF, Jeppesen J (2005) Adult life with Duchenne muscular dystrophy: observations among an emerging and unforeseen patient population. Pediatr Rehabil 8(1):17–28CrossRefPubMedGoogle Scholar
  45. 45.
    Rashbass J, Peake M (2014) The evolution of cancer registration. Eur J Cancer Care 23(6):757–759CrossRefGoogle Scholar
  46. 46.
    Ricotti V, Ridout DA, Pane M, Main M, Mayhew A, Mercuri E et al (2016) The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry 87(2):149–155PubMedGoogle Scholar
  47. 47.
    Rodger S, Lochmuller H, Tassoni A, Gramsch K, Konig K, Bushby K et al (2013) The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases. Orphanet J Rare Dis 8:171CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Rodger S, Woods KL, Bladen CL, Stringer A, Vry J, Gramsch K et al (2015) Adult care for Duchenne muscular dystrophy in the UK. J Neurol 262(3):629–641CrossRefPubMedGoogle Scholar
  49. 49.
    Rodrigues M, Hammond-Tooke G, Kidd A, Love D, Patel R, Dawkins H et al (2012) The New Zealand neuromuscular disease registry. J Clin Neurosci, Off J Neurosurg Soc Australasia 19(12):1749–1750Google Scholar
  50. 50.
    Rodwell C, Ayme S (2015) Rare disease policies to improve care for patients in Europe. Biochim Biophys Acta 1852(10 Pt B):2329–2335CrossRefPubMedGoogle Scholar
  51. 51.
    Sarkozy A, Bushby K, Beroud C, Lochmuller H (2008) 157th ENMC International Workshop: patient registries for rare, inherited muscular disorders 25-27 January 2008 Naarden, The Netherlands. Neuromuscul Disord 18(12):997–1001CrossRefPubMedGoogle Scholar
  52. 52.
    Sawyer SL, Hartley T, Dyment DA, Beaulieu CL, Schwartzentruber J, Smith A et al (2016) Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care. Clin Genet 89(3):275–284CrossRefPubMedGoogle Scholar
  53. 53.
    Scott E, Eagle M, Mayhew A, Freeman J, Main M, Sheehan J et al (2012) Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy. Physiother Res Int, J Research Clin Phys Ther 17(2):101–109CrossRefGoogle Scholar
  54. 54.
    Sparks S, Quijano-Roy S, Harper A, Rutkowski A, Gordon E, Hoffman EP et al (1993) In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, LJH B et al (eds) Congenital muscular dystrophy overview. GeneReviews(R), SeattleGoogle Scholar
  55. 55.
    Taruscio D, Gainotti S, Mollo E, Vittozzi L, Bianchi F, Ensini M et al (2013) The current situation and needs of rare disease registries in Europe. Public Health Genomics 16(6):288–298CrossRefPubMedGoogle Scholar
  56. 56.
    Thompson R, Johnston L, Taruscio D, Monaco L, Beroud C, Gut IG et al (2014) RD-Connect: an integrated platform connecting databases, registries, biobanks and clinical bioinformatics for rare disease research. J Gen Intern Med 29(Suppl 3):S780–S787CrossRefPubMedGoogle Scholar
  57. 57.
    Thompson R, Schoser B, Monckton DG, Blonsky K, Lochmuller H (2009) Patient registries and trial readiness in myotonic dystrophy--TREAT-NMD/Marigold International workshop report. Neuromuscul Disord 19(12):860–866CrossRefPubMedGoogle Scholar
  58. 58.
    Thompson R, Straub V (2016) Limb-girdle muscular dystrophies – international collaborations for translational research. Nat Rev Neurol 12(5):294–309CrossRefPubMedGoogle Scholar
  59. 59.
    TREAT-NMD Neuromuscular Network. Charter for the TREAT-NMD database/registry. http://www.treat-nmd.eu/downloads/file/TGDOC_Charter_2016.pdf. Accessed 1 July 2016
  60. 60.
    TREAT-NMD Neuromuscular Network. TREAT-NMD Global Database Oversight Committee (TGDOC). http://www.treat-nmd.eu/resources/patient-registries/global-registries/governance/. Accessed 1 July 2016
  61. 61.
    TREAT-NMD Neuromuscular Network. TREAT-NMD Registries Toolkit. http://www.treatnmd.eu/resources/patient-registries/tookit/. Accessed 1 July 2016
  62. 62.
    TREAT-NMD Neuromuscular Network. TREAT-NMD: advancing diagnosis, care and treatment for people with neuromuscular diseases around the world. www.treat-nmd.eu. Accessed 1 July 2016
  63. 63.
    van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den Dunnen JT et al (2001) Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 10(15):1547–1554CrossRefPubMedGoogle Scholar
  64. 64.
    Vry J, Gramsch K, Rodger S, Thompson R, Steffensen BF, Rahbek J et al (2016) European cross-sectional survey of current care practices for Duchenne muscular dystrophy reveals regional and age-dependent differences. J Neuromuscul Dis 3(4):517–527CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Wang RT, Nelson SF (2015) What can Duchenne connect teach us about treating Duchenne muscular dystrophy? Curr Opin Neurol 28(5):535–541CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Wang RT, Silverstein Fadlon CA, Ulm JW, Jankovic I, Eskin A, Lu A, et al (2014) Online self-report data for Duchenne muscular dystrophy confirms natural history and can be used to assess for therapeutic benefits. PLoS Curr 17(6)Google Scholar
  67. 67.
    Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A et al (2016) The FAIR guiding principles for scientific data management and stewardship. Sci Data 3:160018CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Willmann R, De Luca A, Benatar M, Grounds M, Dubach J, Raymackers JM et al (2012) Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice. Neuromuscul Disord 22(1):43–49CrossRefPubMedGoogle Scholar
  69. 69.
    Verhaart IEC, Robertson A, Leary R, McMacken G, König K, Kirschner J et al (2017) A multi-source approach to determine SMA incidence and research ready population. J Neurol 264 (7):1465–1473Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Rachel Thompson
    • 1
  • Agata Robertson
    • 1
  • Hanns Lochmüller
    • 1
  1. 1.MRC Centre for Neuromuscular Diseases, Institute of Genetic MedicineNewcastle UniversityNewcastle upon TyneUK

Personalised recommendations